Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Amin J, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Hellard M, Bruneau J, Midgard H, Bourgeois S, Staehelin C, Dore GJ; ACTIVATE Study Group. Grebely J, et al. Among authors: dunlop a. Int J Drug Policy. 2017 Sep;47:177-186. doi: 10.1016/j.drugpo.2017.05.020. Epub 2017 Jun 16. Int J Drug Policy. 2017. PMID: 28624134 Clinical Trial.
Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
Alavi M, Grebely J, Micallef M, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ; Enhancing Treatment for Hepatitis C in Opioid Substitution Settings (ETHOS) Study Group. Alavi M, et al. Among authors: dunlop aj. Clin Infect Dis. 2013 Aug;57 Suppl 2:S62-9. doi: 10.1093/cid/cit305. Clin Infect Dis. 2013. PMID: 23884068
The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study.
Fortier E, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ, Bruneau J, Grebely J; ETHOS Study Group. Fortier E, et al. Among authors: dunlop aj. Int J Drug Policy. 2015 Nov;26(11):1094-102. doi: 10.1016/j.drugpo.2015.06.001. Epub 2015 Jun 11. Int J Drug Policy. 2015. PMID: 26145482
Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study.
Marshall AD, Micallef M, Erratt A, Telenta J, Treloar C, Everingham H, Jones SC, Bath N, How-Chow D, Byrne J, Harvey P, Dunlop A, Jauncey M, Read P, Collie T, Dore GJ, Grebely J. Marshall AD, et al. Among authors: dunlop a. Int J Drug Policy. 2015 Oct;26(10):984-91. doi: 10.1016/j.drugpo.2015.07.002. Epub 2015 Jul 16. Int J Drug Policy. 2015. PMID: 26256938
Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
Keats J, Micallef M, Grebely J, Hazelwood S, Everingham H, Shrestha N, Jones T, Bath N, Treloar C, Dore GJ, Dunlop A; ETHOS Study Group. Keats J, et al. Among authors: dunlop a. Int J Drug Policy. 2015 Oct;26(10):999-1006. doi: 10.1016/j.drugpo.2015.07.006. Epub 2015 Jul 17. Int J Drug Policy. 2015. PMID: 26275578
Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia.
Fortier E, Alavi M, Bruneau J, Micallef M, Perram J, Sockalingam S, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ, Grebely J; ETHOS Study Group. Fortier E, et al. Among authors: dunlop aj. J Addict Med. 2017 Jan/Feb;11(1):10-18. doi: 10.1097/ADM.0000000000000261. J Addict Med. 2017. PMID: 27775955
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B, Backmund M, Robaeys G, Swan T, Marks PS, Quiene S, Applegate TL, Weltman M, Shaw D, Dunlop A, Bruneau J, Midgard H, Bourgeois S, Thurnheer MC, Dore GJ, Grebely J; ACTIVATE Study Group. Cunningham EB, et al. Among authors: dunlop a. BMC Infect Dis. 2017 Jun 13;17(1):420. doi: 10.1186/s12879-017-2517-3. BMC Infect Dis. 2017. PMID: 28610605 Free PMC article. Clinical Trial.
560 results